Companies › Fujian Shengdi Pharmaceutical
13 active drug programs in 28 registered trials: 14 Phase 2, 7 Phase 3, 7 Phase 1; Metabolic and endocrine, Cardiovascular, Other, Gastroenterology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| HRS9531 Injection GLP-1 receptor agonist | GLP1R | Phase 3 | Subjects With Moderate-to-severe OSA and Obesity Who Are on PAP Therapy; Bstructive Sleep Apnea (OSA) and Obesity; Type 2 Diabetes; Obesity … | Dec 2026 |
| HRS-5635 Injection | – | Phase 3 | Nucleos(t)Ide Analogue-suppressed HBeAg-negative Patients With Chronic Hepatitis B; Chronic Hepatitis B | Jan 2027 |
| HRS-9057 injection Radioactively labeled [14C]-HRS-9057 | – | Phase 2 | Fluid Retention Caused by Heart Failure; Fluid Retention Due to Heart Failure | Dec 2026 |
| HRS-9563 Injection | – | Phase 2 | Mild to Moderate Hypertension | Dec 2026 |
| HRS5580 for injection | – | Phase 2 | Prevention of Postoperative Nausea and Vomiting | Dec 2026 |
| HRS-7249 Injection GalNAc-conjugated APOC3-targeted siRNA | APOC3 | Phase 2 | Hyperlipidemia; Severe Hypertriglyceridemia With a High Risk of Acute Pancreatitis | Jan 2027 |
| HRS-4729 | – | Phase 2 | Metabolic Dysfunction-Associated Steatohepatitis (MASH); Overweight/Obesity | Mar 2027 |
| HRS-5632 Injection | – | Phase 2 | Lipoprotein Disorder | Apr 2027 |
| SHR-1918 | – | Phase 2 | Severe Hypertriglyceridemia With a High Risk of Acute Pancreatitis | Jun 2027 |
| HRS-7450 Injection | – | Phase 2 | Acute Ischemic Stroke | – |
| HRS-4139 | – | Phase 1 | Psoriasis Vulgaris | Mar 2027 |
| HRS-5817 Injection | – | Phase 1 | Obesity | Apr 2027 |
| HRS-9531 tablet | – | Phase 1 | Overweight or Obesity | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06391710 | HRS9531 Injection | Phase 2 | Heart Failure With Preserved Ejection Fraction | Cardiovascular | Jan 2026 |
| NCT07150962 | HRS-9531 tablet | Phase 1 | Overweight or Obesity | Metabolic and endocrine | Feb 2026 |
| NCT07318103 | HRS-9057 injection | Phase 2 | Fluid Retention Caused by Heart Failure | Cardiovascular | Sep 2026 |
| NCT07233070 | HRS-7450 Injection | Phase 2 | Acute Ischemic Stroke | Neurology | Sep 2026 |
| NCT06994650 | HRS9531 Injection | Phase 3 | Subjects With Moderate-to-severe OSA and Obesity Who Are on PAP Therapy | Metabolic and endocrine | Dec 2026 |
| NCT06974851 | HRS9531 Injection | Phase 3 | Bstructive Sleep Apnea (OSA) and Obesity | Respiratory | Dec 2026 |
| NCT07681479 | HRS-9057 injection | Phase 1 | Fluid Retention Due to Heart Failure | Cardiovascular | Dec 2026 |
| NCT07709897 | HRS5580 for injection | Phase 2 | Prevention of Postoperative Nausea and Vomiting | Other | Dec 2026 |
| NCT07297797 | HRS-9563 Injection | Phase 2 | Mild to Moderate Hypertension | Cardiovascular | Dec 2026 |
| NCT07540754 | HRS9531 Injection | Phase 1 | Diabetes Mellitus | Metabolic and endocrine | Jan 2027 |
| NCT07100418 | HRS-7249 Injection | Phase 2 | Hyperlipidemia | Metabolic and endocrine | Jan 2027 |
| NCT06425341 | HRS-5635 Injection | Phase 2 | Chronic Hepatitis B | Infectious disease | Jan 2027 |
| NCT07060456 | HRS9531 Injection | Phase 3 | Type 2 Diabetes | Metabolic and endocrine | Feb 2027 |
| NCT07559136 | HRS9531 Injection | Phase 1 | Overweight and Obesity | Metabolic and endocrine | Feb 2027 |
| NCT07285902 | HRS9531 Injection | Phase 3 | Obesity | Metabolic and endocrine | Mar 2027 |
| NCT07807059 | HRS-4729 | Phase 1 | Overweight/Obesity | Metabolic and endocrine | Mar 2027 |
| NCT07802964 | HRS-4139 | Phase 1 | Psoriasis Vulgaris | Immunology | Mar 2027 |
| NCT07185776 | HRS-5632 Injection | Phase 2 | Lipoprotein Disorder | Other | Apr 2027 |
| NCT06934408 | HRS-5817 Injection | Phase 1 | Obesity | Metabolic and endocrine | Apr 2027 |
| NCT07599410 | HRS9531 Injection | Phase 2 | T2DM | Metabolic and endocrine | May 2027 |
| NCT07308392 | HRS-7249 Injection | Phase 2 | Severe Hypertriglyceridemia With a High Risk of Acute Pancreatitis | Gastroenterology | Jun 2027 |
| NCT07308392 | SHR-1918 | Phase 2 | Severe Hypertriglyceridemia With a High Risk of Acute Pancreatitis | Gastroenterology | Jun 2027 |
| NCT07670884 | HRS9531 Injection | Phase 3 | Chronic Management of Body Weight | Other | Oct 2027 |
| NCT07660848 | HRS9531 Injection | Phase 2 | Metabolic Dysfunction-Associated Steatohepatitis (MASH) | Metabolic and endocrine | Mar 2028 |
| NCT07660848 | HRS-4729 | Phase 2 | Metabolic Dysfunction-Associated Steatohepatitis (MASH) | Metabolic and endocrine | Mar 2028 |
| NCT07606950 | HRS-5635 Injection | Phase 3 | Nucleos(t)Ide Analogue-suppressed HBeAg-negative Patients With Chronic Hepatitis B | Infectious disease | Jun 2028 |
| NCT07799688 | HRS-7249 Injection | Phase 2 | Hyperlipidemia | Metabolic and endocrine | Oct 2028 |
| NCT07551492 | HRS9531 Injection | Phase 3 | Atherosclerotic Cardiovascular Disease | Cardiovascular | May 2031 |
Shanghai Minwei Biotechnology Beijing QL Biopharmaceutical Hudson Biotech Shenzhen Salubris Pharmaceuticals Gan & Lee Pharmaceuticals.
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.